Literature DB >> 16370927

An update on the use of ophthalmic ketorolac tromethamine 0.4%.

Henry D Perry1, Eric D Donnenfeld.   

Abstract

Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have demonstrated that ketorolac tromethamine 0.4% has equivalent efficacy to ketorolac tromethamine 0.5% in reducing postsurgical inflammation and controlling pain. Several studies have demonstrated that, as well as reducing pain and ocular inflammation, ketorolac tromethamine 0.4% effectively treats cystoid macular oedema, inhibits miosis and may prevent cystoid macular oedema when used both pre- and postoperatively. Ketorolac tromethamine 0.4% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16370927     DOI: 10.1517/14656566.7.1.99

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  8 in total

Review 1.  Ketorolac 0.45% ophthalmic solution.

Authors:  Paul L McCormack
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

2.  A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery.

Authors:  Helga P Sandoval; Luis E Fernández de Castro; David T Vroman; Kerry D Solomon
Journal:  Clin Ophthalmol       Date:  2007-12

3.  Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.

Authors:  Hyung Cho; Kenneth J Wolf; Eric J Wolf
Journal:  Clin Ophthalmol       Date:  2009-06-02

4.  Ocular pharmacokinetics of 0.45% ketorolac tromethamine.

Authors:  Mayssa Attar; Rhett Schiffman; Lisa Borbridge; Quinn Farnes; Devin Welty
Journal:  Clin Ophthalmol       Date:  2010-12-01

5.  Etiology and treatment of the inflammatory causes of cystoid macular edema.

Authors:  Hyung Cho; Assumpta Madu
Journal:  J Inflamm Res       Date:  2009-10-02

6.  Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes.

Authors:  Seok Hyeon Song; Seung Kook Baek; Min Woo Lee; Young Hoon Lee
Journal:  Korean J Ophthalmol       Date:  2020-02

7.  The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery.

Authors:  Ji Won Jung; Byung Hoon Chung; Eung Kweon Kim; Kyoung Yul Seo; Tae-im Kim
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

8.  Studies on Surfactants, Cosurfactants, and Oils for Prospective Use in Formulation of Ketorolac Tromethamine Ophthalmic Nanoemulsions.

Authors:  Shahla S Smail; Mowafaq M Ghareeb; Huner K Omer; Ali A Al-Kinani; Raid G Alany
Journal:  Pharmaceutics       Date:  2021-03-30       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.